ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
72 announcements with these filters
Lupin Inc. licensed two oncology programs to Kaveri Therapeutics in exchange for an 82.2% stake, valued at ₹15.36 Crore.
Lupin Ltd has submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the period ended June 30, 2026. This disclosure details the current equity distribution structure.
Lupin Limited scheduled its 44th AGM for August 4, 2026. Key agenda items include adopting financial statements, declaring dividends, and appointing Deloitte Haskins & Sells as statutory auditors.
Lupin Limited has submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report details the company's environmental, social, and governance performance.
Lupin Limited will hold its 44th AGM on August 4, 2026. The record date for the final dividend of ₹18 per share is July 17, 2026.
Lupin Ltd allotted 2,358 shares under ESOP. This increases its paid-up capital to ₹91.44 Crore.
Lupin received an EIR from the U.S. FDA for its Somerset facility. The inspection resulted in a satisfactory VAI classification.
Lupin's subsidiary Nanomi completed the acquisition of shares in MPPI. This increases Nanomi's effective shareholding in MPPI to 99.89%.
Lupin Limited approved granting 65,251 stock options under its 2025 scheme. Options vest over three years subject to performance conditions.
Lupin received tentative U.S. FDA approval for Enzalutamide Tablets. The approval covers strengths of 40mg, 80mg, 120mg, and 160mg.
Lupin collaborated with Laboratorios ERN S.A. to launch its Luforbec inhaler in Spain. This strategic partnership expands Lupin's respiratory market footprint into the Spanish therapeutic sector.
Lupin received U.S. FDA approval for Ranluspec, an interchangeable biosimilar for Lucentis. This milestone expands the company's ophthalmology portfolio in the American market.
Lupin Limited allotted 16,673 equity shares following the exercise of vested employee stock options. This increases the company's total paid-up share capital to 45,72,32,536 shares.
Lupin and Natco received U.S. FDA approval for Eribulin Mesylate Injection. The reference drug has estimated annual U.S. sales of ₹415.15 Crore.
Lupin received U.S. FDA approval for its Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride tablets. The product targets a USD 132.8 million market.
Lupin Limited announced that the acquisition of minority shareholding in Multicare Pharmaceuticals Philippines is ongoing. Completion is now expected in July 2026, pending closing conditions.
Lupin shared positive Phase 1 trial results for its novel SOS1 inhibitor, LNP8701, at ASCO 2026. The drug demonstrated safety and favorable anti-tumor activity in metastatic patients.
Lupin received Chinese regulatory approval for Oseltamivir Phosphate Oral Suspension, marking its first product entry into China. This milestone strengthens its global footprint in paediatric care.
Lupin Limited filed its Annual Secretarial Compliance Report for FY2026. The report by Makarand M. Joshi & Co. confirms regulatory adherence with no major non-compliances noted.
Lupin debuted in the Dow Jones Best-in-Class Indices for 2026. This prestigious inclusion recognizes the company's industry-leading ESG performance and sustainability leadership.
Lupin received tentative U.S. FDA approval for Revefenacin Inhalation Solution, targeting a USD 260.7 million market. This strengthens Lupin's respiratory portfolio in the United States.
Lupin reported record FY26 revenues of ₹27,958 cr (up 23%) and EBITDA of ₹8,160 cr (up 55%). Management focuses on complex products and India prescription growth.
Lupin received US FDA approval for Famotidine Injection, targeting an $8.7 million market. This ₹82.65 Crore opportunity strengthens its presence in the US gastrointestinal segment.
Lupin delivered a record-breaking FY26 with 32% revenue growth and 68% EBITDA surge, driven by US generic exclusivity and robust India prescription growth.
Lupin Limited recommended a final dividend of ₹18 per equity share for FY 2026. This 900% payout remains subject to shareholder approval at the AGM.
Lupin recommended appointing Deloitte Haskins & Sells as Statutory Auditors for five years. This follows the tenure completion of current auditors B S R & Co. LLP.
Lupin reported strong Q4 FY26 results with sales reaching ₹73,919 mn, up 33% YoY, driven by a 55% surge in North American markets.
Lupin reported FY2026 sales of ₹27487.50 Crore, reflecting 23.9% annual growth. Strong performance in U.S. and India markets drove significant margin expansion and profitability.
Lupin Limited recommended appointing Deloitte Haskins & Sells as Statutory Auditors for a five-year term. This regulatory move follows the term completion of existing auditors.
Lupin Ltd reported revenue from operations of ₹7,475 Cr (+31.9% YoY) and net profit of ₹1,469 Cr (+87.7% YoY) for Q4 FY26.